Accessibility Menu
OS Therapies logo

OS Therapies(NYSEMKT) OSTX

Market Cap$74.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-35%
5 YearN/A
1 Year-6%
1 Month-14%
$1.63
+5.16%
+0.08Today
After hours$1.64+$0.01 (+0.31%)
OS Therapies last closing stock price
MetricPriceDate
Last closeUSD 1.632026-08-04
OS Therapies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.67%USD 1.502026-07-28
1 month-13.76%USD 1.892026-07-02
3 month-5.78%USD 1.732026-05-06
Year to date+16.43%USD 1.402025-12-31
1 year-5.78%USD 1.732025-08-04
Since inception-35.06%USD 2.512024-08-01

OS Therapies Financials at a Glance

Market Cap

$74.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$35.27M

EPS (TTM)

-$1.03

P/E Ratio

-1.59

Dividend

$0.00

Beta (Volatility)

1.60 (High)

Price

$1.63

Volume

348,855.41

Open

$1.55

Previous Close

$1.63

Daily Range

$1.55 - $1.64

52-Week Range

$1.15 - $2.57

Estimated Earnings Date

Aug 17, 2026

OSTX News

Foolcom-Featured.png

Os Therapies Posts Wider Loss in Q2

Motley Fool Markets TeamAug 19, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OS Therapies

OS Therapies develops new treatments for rare bone cancers. Its main products aim to help children and adults with limited options. The company focuses on therapies that target hard-to-treat tumors.

Lab Coats & Cancer: What OS Therapies Sells

  • OST-HER2 Immunotherapy: Off-the-shelf treatment for osteosarcoma, a rare bone cancer; no revenue yet.
  • OST-tADC Platform: Preclinical antibody-drug conjugate technology for targeted cancer therapy; no revenue yet.
  • Acquired Lm-based Programs: Immune-oncology assets for lung and prostate cancer, acquired in 2025; no revenue yet.

Growth Spurts & Strategic Moves

  • Acquired HER2 assets from Ayala Pharmaceuticals in 2025 for $8 million.
  • Completed Phase IIb trial for OST-HER2 in 2025, showing improved survival rates.
  • Launched ATM equity program in August 2025 to raise capital.
  • Expanded regulatory filings to the UK and EU, with submissions planned for 2026.

Why OS Therapies Is a Bit Different

The company targets rare pediatric cancers with few treatment options. Its technology allows for customizable drug delivery to tumors. OS Therapies relies on partnerships and outsourced manufacturing to stay flexible.

Five Things You Need to Know

  • No commercial revenue reported for 2023, 2024, or 2025.
  • Operating loss was $28.7 million in 2025, up 321.3% from 2024.
  • Cash balance fell to $0.3 million at end of 2025, down from $5.5 million in 2024.
  • R&D expenses rose to $16.4 million in 2025, up 476.6% from 2024.

Bottom Line

OS Therapies is a small, research-focused biotech tackling rare cancers. The company faces high costs and relies on outside funding to continue its work.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Paul A. Romness

Website

www.ostherapies.com

Headquarters

Grasonville, MD 21638, US

OSTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2584.39%

Return on Capital

N/A

Return on Assets

-483.25%

Earnings Yield

-62.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$74.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

45.54M

Volume

348.86K

Avg. Volume

689.67K

Financials (TTM)

Gross Profit

-$362.39K

Operating Income

-$33.87M

EBITDA

-$34.71M

Operating Cash Flow

-$15.36M

Capital Expenditure

-$316.42K

Free Cash Flow

-$15.68M

Cash & ST Invst.

$917.55K

Total Debt

$1.34M

OS Therapies Performance Analysis

OS Therapies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
OS Therapies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
OS Therapies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.31-99.9%
20232023-12-31USD -0.3722.4%
20242024-12-31USD -0.5239.5%
20252025-12-31USD -0.9888.4%
OS Therapies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-16.7%
Q42025-12-31-95.2%
Q12026-03-3134.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$124.94K

N/A

Gross Margin

0.00%

N/A

Market Cap

$74.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$14.85M

N/A

Employees

5

N/A

Net Income

-$10.40M

-168.2%

EBITDA

-$10.20M

-163.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$917.55K

-69.1%

Total Debt

$1.34M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.34M

N/A

Return on Assets

-4.83%

N/A

Return on Invested Capital

3.51%

N/A

Free Cash Flow

-$4.56M

-27.1%

Operating Cash Flow

-$4.56M

-32.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EQEquillium, Inc.
$2.26+2.73%
SPRBSpruce Biosciences, Inc.
$46.26+7.23%
INKTMiNK Therapeutics, Inc.
$11.07+3.55%
NRXPNRx Pharmaceuticals, Inc.
$3.05-5.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About OSTX

What is the current price of OS Therapies?

OS Therapies is trading at $1.63 per share.

What is the 52-week range for OS Therapies?

Over the past 52 weeks, OS Therapies has traded between $1.15 and $2.57.

How much debt does OS Therapies have?

As of the most recent reporting period, OS Therapies reported total debt of $1.34M.

How much cash does OS Therapies have on hand?

OS Therapies reported $917.55K in cash and cash equivalents in its most recent financial results.

What is OS Therapies’s dividend yield?

OS Therapies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services